Janney Capital Management LLC Has $21.88 Million Stake in Pfizer, Inc. (NYSE:PFE)

Janney Capital Management LLC reduced its position in Pfizer, Inc. (NYSE:PFE) by 1.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 639,488 shares of the biopharmaceutical company’s stock after selling 6,464 shares during the period. Pfizer makes up approximately 1.0% of Janney Capital Management LLC’s portfolio, making the stock its 28th largest position. Janney Capital Management LLC’s holdings in Pfizer were worth $21,876,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of PFE. Cypress Capital Management LLC increased its position in shares of Pfizer by 2.0% in the fourth quarter. Cypress Capital Management LLC now owns 414,745 shares of the biopharmaceutical company’s stock worth $13,471,000 after buying an additional 8,080 shares in the last quarter. Wilkins Investment Counsel Inc. increased its position in shares of Pfizer by 4.5% in the fourth quarter. Wilkins Investment Counsel Inc. now owns 269,073 shares of the biopharmaceutical company’s stock worth $8,739,000 after buying an additional 11,600 shares in the last quarter. Greytown Advisors Inc. bought a new position in shares of Pfizer during the fourth quarter worth approximately $284,000. Stellar Capital Management LLC bought a new position in shares of Pfizer during the fourth quarter worth approximately $433,000. Finally, Asset Management One Co. Ltd. increased its position in shares of Pfizer by 618.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,094,592 shares of the biopharmaceutical company’s stock worth $360,362,000 after buying an additional 9,550,335 shares in the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.

Pfizer, Inc. (NYSE:PFE) traded down 0.85% on Friday, hitting $32.67. 15,490,145 shares of the company’s stock were exchanged. The company has a market cap of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00. The company’s 50-day moving average price is $33.33 and its 200-day moving average price is $33.37. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 EPS. Analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.92%. Pfizer’s dividend payout ratio is presently 94.12%.

COPYRIGHT VIOLATION NOTICE: This story was first reported by BNB Daily and is the property of of BNB Daily. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/janney-capital-management-llc-sells-6464-shares-of-pfizer-inc-nysepfe-updated-updated-updated.html.

PFE has been the topic of a number of research analyst reports. Sanford C. Bernstein restated a “buy” rating and issued a $35.00 target price on shares of Pfizer in a research note on Monday, April 24th. BMO Capital Markets restated a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th. Barclays PLC reiterated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Wednesday, May 3rd. Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $37.61.

In other news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply